Solid Formulation of a Recombinant Anthrax Vaccine

Pfenex and Glide Pharma have an ongoing collaboration to develop an anthrax vaccine containing the recombinant protective antigen (rPA) from Bacillus anthracis produced using Pfēnex expression technology, which is suitable for delivery with the Glide SDI (solid dose injection) technology.

This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage at room temperature and ease of administration.

Download to find out more.

More About This Company